These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 10662396)

  • 1. Economic evaluation of ciprofloxacin compared with usual antibacterial care for the treatment of acute exacerbations of chronic bronchitis in patients followed for 1 year.
    Torrance G; Walker V; Grossman R; Mukherjee J; Vaughan D; La Forge J; Lampron N
    Pharmacoeconomics; 1999 Nov; 16(5 Pt 1):499-520. PubMed ID: 10662396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 1-year community-based health economic study of ciprofloxacin vs usual antibiotic treatment in acute exacerbations of chronic bronchitis: the Canadian Ciprofloxacin Health Economic Study Group.
    Grossman R; Mukherjee J; Vaughan D; Eastwood C; Cook R; LaForge J; Lampron N
    Chest; 1998 Jan; 113(1):131-41. PubMed ID: 9440580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and economic considerations in the treatment of acute exacerbations of chronic bronchitis.
    Destache CJ; Dewan N; O'Donohue WJ; Campbell JC; Angelillo VA
    J Antimicrob Chemother; 1999 Mar; 43 Suppl A():107-13. PubMed ID: 10225580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of gemifloxacin: results from the GLOBE study.
    Halpern MT; Palmer CS; Zodet M; Kirsch J
    Am J Health Syst Pharm; 2002 Jul; 59(14):1357-65. PubMed ID: 12132563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute exacerbations of chronic bronchitis: a pharmacoeconomic review of antibacterial use.
    Morris S; Anderson P; Irwin DE
    Pharmacoeconomics; 2002; 20(3):153-68. PubMed ID: 11929346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Etiology, susceptibility, and treatment of acute bacterial exacerbations of complicated chronic bronchitis in the primary care setting: ciprofloxacin 750 mg b.i.d. versus clarithromycin 500 mg b.i.d. Bronchitis Study Group.
    Anzueto A; Niederman MS; Tillotson GS
    Clin Ther; 1998; 20(5):885-900. PubMed ID: 9829441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized, double-blind study of prulifloxacin versus ciprofloxacin in patients with acute exacerbations of chronic bronchitis.
    Grassi C; Salvatori E; Rosignoli MT; Dionisio P;
    Respiration; 2002; 69(3):217-22. PubMed ID: 12097764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy and safety of a new ciprofloxacin suspension compared with co-amoxiclav tablets in the treatment of acute exacerbations of chronic bronchitis.
    Read RC; Kuss A; Berrisoul F; Kearsley N; Torres A; Kubin R
    Respir Med; 1999 Apr; 93(4):252-61. PubMed ID: 10464889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and cost-effectiveness of antibiotic treatments for community acquired pneumonia (CAP) and acute exacerbations of chronic bronchitis (AECB).
    Lavoie F; Blais L; Castilloux AM; Scalera A; LeLorier J
    Can J Clin Pharmacol; 2005; 12(2):e212-7. PubMed ID: 15998960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of twice-daily ciprofloxacin 750 mg in the treatment of patients with acute exacerbations of chronic bronchitis and pneumonia.
    Pryka R; Kowalsky S; Haverstock D
    Clin Ther; 1998; 20(1):141-55. PubMed ID: 9522111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
    Haentjens P; De Groote K; Annemans L
    Arch Orthop Trauma Surg; 2004 Oct; 124(8):507-17. PubMed ID: 15365714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment cost of acute exacerbations of chronic bronchitis.
    Niederman MS; McCombs JS; Unger AN; Kumar A; Popovian R
    Clin Ther; 1999 Mar; 21(3):576-91. PubMed ID: 10321424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The economic impact of acute exacerbations of chronic bronchitis in the United States and Canada: a literature review.
    Halpern MT; Higashi MK; Bakst AW; Schmier JK
    J Manag Care Pharm; 2003; 9(4):353-9. PubMed ID: 14613454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The excess cost of acute exacerbations of chronic bronchitis in patients aged 45 and older in England and Wales.
    McGuire A; Irwin DE; Fenn P; Gray A; Anderson P; Lovering A; MacGowan A
    Value Health; 2001; 4(5):370-5. PubMed ID: 11705127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute exacerbations of chronic bronchitis: what role for the new fluoroquinolones?
    Obaji A; Sethi S
    Drugs Aging; 2001; 18(1):1-11. PubMed ID: 11232735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The safety and efficacy of short course (5-day) moxifloxacin vs. azithromycin in the treatment of patients with acute exacerbation of chronic bronchitis.
    DeAbate CA; Mathew CP; Warner JH; Heyd A; Church D
    Respir Med; 2000 Nov; 94(11):1029-37. PubMed ID: 11127487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute exacerbation of chronic bronchitis: disease-specific issues that influence the cost-effectiveness of antimicrobial therapy.
    Saint S; Flaherty KR; Abrahamse P; Martinez FJ; Fendrick AM
    Clin Ther; 2001 Mar; 23(3):499-512. PubMed ID: 11318083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of ciprofloxacin and clarithromycin in acute bacterial exacerbations of complicated chronic bronchitis: interim analysis. Bronchitis Study Group.
    Anzueto A; Niederman MS; Haverstock DC; Tillotson GS
    Clin Ther; 1997; 19(5):989-1001. PubMed ID: 9385486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of Corticosteroid Nasal Spray vs Surgical Therapy in Patients With Severe to Extreme Anatomical Nasal Obstruction.
    Teti VP; Akdagli S; Most SP
    JAMA Facial Plast Surg; 2016 May; 18(3):165-70. PubMed ID: 26747790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 1-year prospective cost-effectiveness analysis of roflumilast for the treatment of patients with severe chronic obstructive pulmonary disease.
    Rutten-van Mölken MP; van Nooten FE; Lindemann M; Caeser M; Calverley PM
    Pharmacoeconomics; 2007; 25(8):695-711. PubMed ID: 17640111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.